Emergent BioSolutions Inc. (NYSE: EBS) announced a leadership transition within its finance department on October 16, 2026. The company disclosed that Richard S. Lindahl, Executive Vice President and Chief Financial Officer, will retire from his role effective December 31, 2026. Following his retirement, Mr. Lindahl will serve as a senior executive advisor to the company from January 1 through March 31, 2027.
To ensure continuity, the Board of Directors has appointed Frank Vargo, the company's current Vice President of Treasurer, as Interim Chief Financial Officer. Mr. Vargo will assume the principal financial and accounting officer responsibilities effective January 1, 2027.
Mr. Vargo, age 43, joined Emergent in December 2019 as Director of Corporate FP&A and G&A and was promoted to Vice President, Treasurer in November 2025. Prior to joining the company, he held finance roles at Under Armor, Inc., and in the aerospace and defense industry. He holds an MBA from Texas A&M University and a bachelor’s degree in engineering from the Georgia Institute of Technology.
In connection with this appointment, the Board approved interim compensation for Mr. Vargo, consisting of an additional $3,850 per pay period added to his current base salary of $328,000. His salary, bonus, and equity awards will remain commensurate with his previous seniority and will be reviewed on the same cycle as other executive officers.
Mr. Lindahl has served as CFO for over eight years. Before joining Emergent in 2018, he served as CFO of CEB, SVP and treasurer of Sprint Nextel Corporation, and held various positions at MCI Communications Corp. and Deloitte & Touche LLP. He currently serves on the board of directors of Compass Therapeutics, Inc.
CEO Joe Papa stated that Mr. Vargo has been integral to driving strategic priorities and that the company is confident he will ensure continuity and disciplined financial stewardship during the transition.
